CAS: 1951431-22-3
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | BKI-1369 REF: 3D-BDD43122CAS: 1951431-22-3 | Min. 95% | A consultar | Lun 13 Ene 25 |
 | BKI-1369 REF: TM-T10556CAS: 1951431-22-3 | - - - | 158,00 €~2.340,00 € | Mar 21 Ene 25 |
BKI-1369
CAS:1951431-22-3
BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied …
Fórmula:
C23H27N7O
Pureza:
Min. 95%
Peso molecular:
417.51 g/mol
Ref: 3D-BDD43122
| 1mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Entrega estimada en Estados Unidos, el Lunes 13 de Enero de 2025
BKI-1369
CAS:1951431-22-3
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
Fórmula:
C23H27N7O
Forma y color:
Solid
Peso molecular:
417.51
Ref: TM-T10556
| 5mg | 444,00 € | ||
| 25mg | 1.410,00 € | ||
| 50mg | 1.854,00 € | ||
| 100mg | 2.340,00 € |
Entrega estimada en Estados Unidos, el Martes 21 de Enero de 2025
